OMERS ADMINISTRATION Corp Acquires New Position in Revolution Medicines, Inc. $RVMD

OMERS ADMINISTRATION Corp bought a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 2,308 shares of the company’s stock, valued at approximately $432,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Meeder Advisory Services Inc. boosted its position in shares of Revolution Medicines by 3.0% in the first quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock worth $401,000 after purchasing an additional 120 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Revolution Medicines by 1.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock worth $802,000 after purchasing an additional 125 shares in the last quarter. Deutsche Bank AG raised its position in shares of Revolution Medicines by 0.4% during the 4th quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock valued at $2,566,000 after purchasing an additional 130 shares during the period. Contravisory Investment Management Inc. bought a new stake in shares of Revolution Medicines during the 2nd quarter valued at $32,000. Finally, Johnson Financial Group Inc. bought a new stake in shares of Revolution Medicines during the 2nd quarter valued at $37,000. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Trading Up 2.7%

Revolution Medicines stock opened at $221.15 on Friday. Revolution Medicines, Inc. has a 1 year low of $37.56 and a 1 year high of $224.31. The firm’s 50 day moving average price is $192.43 and its 200-day moving average price is $148.17. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The stock has a market cap of $47.40 billion, a P/E ratio of -25.07 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the previous year, the company posted ($1.31) EPS. On average, equities analysts predict that Revolution Medicines, Inc. will post -8.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RVMD has been the subject of several recent analyst reports. Oppenheimer upped their target price on shares of Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a report on Friday, July 17th. Truist Financial boosted their price objective on Revolution Medicines from $231.00 to $239.00 and gave the company a “buy” rating in a research report on Thursday. TD Cowen upgraded Revolution Medicines to a “strong-buy” rating in a research report on Monday. Finally, Wolfe Research reaffirmed an “outperform” rating and issued a $220.00 price objective on shares of Revolution Medicines in a research note on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $193.28.

Insider Buying and Selling

In other Revolution Medicines news, COO Margaret A. Horn sold 29,600 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $160.12, for a total value of $4,739,552.00. Following the sale, the chief operating officer owned 154,647 shares in the company, valued at $24,762,077.64. The trade was a 16.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Stephen Michael Kelsey sold 4,175 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total transaction of $651,801.00. Following the transaction, the insider directly owned 291,876 shares of the company’s stock, valued at $45,567,681.12. This trade represents a 1.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 212,497 shares of company stock worth $38,206,486 in the last 90 days. 7.60% of the stock is owned by company insiders.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.